Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: john.d who wrote (6830)	2/28/2001 8:23:46 AM
From: pull_da_trigger	Respond to of 14101

I'm recently a new investor in DMX and have gone over the last few months of posts. However, I don't have the time or inclination to read the last 2-3 years of posts. I'm sure that there are other recent investors that aren't fully up to speed on DMX's potential. I checked out the wf10 web site and was quite impressed. Here are some of the interesting WF10 facts I've gleaned over the last couple of days: From dimethaid.com ("President's message" and "About Dimethaid/Our Products/WF10") Dimethaid owns 20% of a company called Oxo Chemie. Oxo Chemie is the holder of the patent rights to "TCDO" which adjusts the body's immune system. They also hold the patent rights to WF10 which is a dilution of TCDO for use as an immune modulator in clinical trials for the treatment fo HIV/AIDS and cancer. Dimethaid also has an exclusive right to develop and distribute WF10 and related products in Canada for a term of 20 years. "Two successful Phase II studies of WF10 have been completed." "Multi-centre Phase III pivotal trial with 240 patients with late-stage HIV" "We were very encouraged by Oxo Chemie's completion of enrollment in their pivotal Phase III trial with WF10 for the treatment of HIV/AIDS, by the end of the summer. The treatment phase has been completed and we now anxiously await completion of the study after the follow-up period." From wf10.com "A placebo controlled trial of 19 seriously, impaired AIDS sufferers: 9 received placebo, 10 received WF-10 with 4 cycles of the treatment. And afterwards they could receive any combination of F.D.A. Approved therapy. Nine months later, six placebo patients had died while one of the WF-10 had died. Follow-up revealed that as of last year, 8 of 10 WF-10 patients remained alive while the entire placebo group had died. WF-10 will become a major standard in HIV treatment and will then be fully investigated for it's anti-cancer properties." "latest patient results female pt. with inoperable lung cancer, due to site, had two cycles of drug, followed by radiation, followed by 2 more cycles of wf10--- results recent chest xray read as negative, with no signs of the tumor mass, ... I am not saying this person is cured, however I believe she is in remission, and will continue with her wf10 treatment. anecdotal report of wf10 used in multiple sclerosis, with arrested progression of the disease, and improved gait, and balance. (where previously used wheelchair at times.) anecdotal report of wf10 for crohn's disease, with BM's back to normal,pain and diarrhea gone, and return of ability to eat a variety of foods. newest patient is non-hodgkin's lymphoma, check for updated results next month."